for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Pharming Group announces acquisition of all North American commercialisation rights to Ruconest from Valeant

Aug 9 (Reuters) - Pharming Group NV :

* Announces acquisition of all North American commercialisation rights to Ruconest from Valeant

* $125 million deal value, with an upfront fee for Valeant of US$60 million, and self-funding sales milestone payments up to a further US$65 million in total

* Funding through a combination of straight debt and new equity capital of between US$ 80-100 million Source text for Eikon: Further company coverage: (Gdynia Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up